Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Activists Challenge Gilead’s Patents on Costly Hepatitis C Drug Sovaldi
Patent for hepatitis C treatment would cut access for millions, groups say
High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents
Gilead denied patent for hepatitis C drug sofosbuvir in India
Gilead denied patent for hepatitis C drug sofosbuvir in India
India rejects Gilead’s Hepatitis C drug patent request
Indian health activists move to prevent Gilead’s drug patent
US group seeks to block Gilead drug patent in India
Hepatitis C drug: US group opposes Gilead’s patent request in India
Gilead attempt to secure patent on hepatitis C drug opposed in India